Savara (NASDAQ:SVRA) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Savara (NASDAQ:SVRA) from a hold rating to a sell rating in a research note released on Saturday morning.

A number of other research firms also recently weighed in on SVRA. Oppenheimer began coverage on Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Stock Up 2.1%

Savara stock opened at $5.38 on Friday. The company’s 50-day moving average is $5.65 and its 200-day moving average is $5.48. The firm has a market capitalization of $1.11 billion, a PE ratio of -9.28 and a beta of 0.29. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 13.47. Savara has a fifty-two week low of $2.92 and a fifty-two week high of $7.01.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Sell-side analysts anticipate that Savara will post -0.62 earnings per share for the current year.

Hedge Funds Weigh In On Savara

A number of hedge funds have recently bought and sold shares of SVRA. BlackRock Inc. acquired a new position in shares of Savara in the 2nd quarter valued at about $76,966,000. Polar Capital Holdings Plc acquired a new stake in Savara in the 4th quarter valued at $50,086,000. RTW Investments LP acquired a new position in shares of Savara during the fourth quarter valued at about $35,893,000. VR Adviser LLC increased its holdings in Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after purchasing an additional 5,626,624 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Savara during the fourth quarter worth $27,496,000. Institutional investors own 87.93% of the company’s stock.

Savara News Roundup

Here are the key news stories impacting Savara this week:

• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.62 from a loss of $0.59, below the current consensus estimate of a $0.57 loss. Quarterly estimates were also reduced to losses of $0.16 for the third quarter and $0.15 for the fourth quarter.
• Negative Sentiment: The firm cut its 2027 EPS forecast to a loss of $0.37 from $0.34 and its 2028 forecast to a loss of $0.06 from $0.04, indicating continued operating losses over the next several years.
• Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was lowered to $0.09 from $0.11, while 2030 EPS was cut to $0.37 from $0.39. Although these forecasts still point to eventual profitability, the reductions weaken the near- and long-term earnings outlook.
• Neutral Sentiment: The revisions follow Savara’s recent quarterly results, in which the company reported a $0.16-per-share loss versus the $0.14 loss analysts expected. Investors may therefore remain focused on cash usage, execution and progress toward commercialization.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.